All Updates

All Updates

icon
Filter
Partnerships
BenevolentAI and AstraZeneca extends collaboration with novel target for systemic lupus erythematosus
AI Drug Discovery
Jun 25, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 25, 2024

BenevolentAI and AstraZeneca extends collaboration with novel target for systemic lupus erythematosus

Partnerships

  • AI-powered biotechnology company BenevolentAI, in collaboration with AstraZeneca, has announced that a novel target for systemic lupus erythematosus (SLE) has been added to its discovery portfolio.

  • The partnership, initiated in 2019, leverages BenevolentAI's AI drug discovery platform to develop novel therapeutic targets tested and validated by AstraZeneca. The collaborative research was initiated focusing on idiopathic pulmonary fibrosis and chronic kidney disease and was extended in 2022 , expanding the study to include heart failure and SLE.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.